Stock Market Wire News Logo
Stock Market Wire News Logo
    • Login
    • Sign Up

Ad

Investor Relations

JAZZ News and Press Jazz Pharmaceuticals plc


home / stock / jazz / jazz news

RSS
JAZZ JAZZ Quote JAZZ Short JAZZ News JAZZ Articles JAZZ Message Board

News | Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

  • JAZZ - Jazz Pharmaceuticals names Renee Gala as CEO

    2025-07-10 07:54:49 ET More on Jazz Pharmaceuticals Jazz Pharmaceuticals: I See Big Potential In This Stock As An Investor Jazz Pharmaceuticals: One Step Forward, One Back Jazz Pharmaceuticals gets EU nod for Ziihera Read the full article on Seeking Alpha ...

    • July 10, 2025 07:54:49 am
    • |
    • SeekingAlpha
    • |
      • JAZZ Stock
      • JAZZ Quote
      • JAZZ Short
      • JAZZ News
      • JAZZ Articles
      • JAZZ Message Board
  • JAZZ - Jazz Pharmaceuticals Names Renee Gala as President and Chief Executive Officer

    Jazz Pharmaceuticals Names Renee Gala as President and Chief Executive Officer PR Newswire – Selection Follows Robust Succession Process Led by the Board – – Bruce Cozadd to Retire as CEO and Remain Chairperson of the Board of Directors ȁ...

    • July 10, 2025 07:30:00 am
    • |
    • PR Newswire
    • |
      • JAZZ Stock
      • JAZZ Quote
      • JAZZ Short
      • JAZZ News
      • JAZZ Articles
      • JAZZ Message Board
  • JAZZ - Jazz Pharmaceuticals: I See Big Potential In This Stock As An Investor

    2025-07-07 09:30:00 ET Jazz Pharmaceuticals plc's (NASDAQ: JAZZ ) stock price has continued to fluctuate between $97 and $120 over the past three months, even as it has made significant progress in developing its oncology franchise.... Read the full article on Seeking Alph...

    • July 07, 2025 09:30:00 am
    • |
    • SeekingAlpha
    • |
      • JAZZ Stock
      • JAZZ Quote
      • JAZZ Short
      • JAZZ News
      • JAZZ Articles
      • JAZZ Message Board
  • JAZZ - Jazz Pharmaceuticals gets EU nod for Ziihera

    2025-07-01 09:52:26 ET More on Jazz Pharmaceuticals Jazz Pharmaceuticals: One Step Forward, One Back Jazz Pharmaceuticals plc (JAZZ) Q1 2025 Earnings Call Transcript Jazz Pharma gets FDA priority review for lung cancer therapy Zepzelca Jazz Pharmaceuticals su...

    • July 01, 2025 09:52:26 am
    • |
    • SeekingAlpha
    • |
      • JAZZ Stock
      • JAZZ Quote
      • JAZZ Short
      • JAZZ News
      • JAZZ Articles
      • JAZZ Message Board
  • JAZZ - Jazz Pharmaceuticals Receives European Commission Marketing Authorization for Ziihera® (zanidatamab) for the Treatment of Advanced HER2-Positive Biliary Tract Cancer

    Jazz Pharmaceuticals Receives European Commission Marketing Authorization for Ziihera® (zanidatamab) for the Treatment of Advanced HER2-Positive Biliary Tract Cancer PR Newswire – Conditional approval based on positive results from the HERIZON-BTC-01 Phase 2b t...

    • July 01, 2025 08:31:00 am
    • |
    • PR Newswire
    • |
      • JAZZ Stock
      • JAZZ Quote
      • JAZZ Short
      • JAZZ News
      • JAZZ Articles
      • JAZZ Message Board
  • JAZZ - Stoke Therapeutics: Impressive Pipeline And Big Backers

    2025-06-15 23:27:38 ET Headquartered in Bedford, MA, Stoke Therapeutics ( STOK ) was founded in 2014 with a focus on developing RNA-based medicines to treat severe diseases by increasing protein expression.... Read the full article on Seeking Alpha For further details see: ...

    • June 15, 2025 11:27:38 pm
    • |
    • SeekingAlpha
    • |
      • JAZZ Stock
      • JAZZ Quote
      • JAZZ Short
      • JAZZ News
      • JAZZ Articles
      • JAZZ Message Board
  • JAZZ - Amgen: Imdelltra Data And Q1 Results Impress

    2025-06-14 10:30:00 ET Despite the war between Israel and Iran that began on June 13 , Amgen's ( AMGN ) stock price continues to hold above its VWAP [volume-weighted average price] and has gained about 15% in the last month.... Read the full article on Seeking ...

    • June 14, 2025 10:30:00 am
    • |
    • SeekingAlpha
    • |
      • JAZZ Stock
      • JAZZ Quote
      • JAZZ Short
      • JAZZ News
      • JAZZ Articles
      • JAZZ Message Board
  • JAZZ - Jazz Pharma gets FDA priority review for lung cancer therapy Zepzelca

    2025-06-10 08:36:39 ET More on Jazz Pharmaceuticals Jazz Pharmaceuticals: One Step Forward, One Back Jazz Pharmaceuticals plc (JAZZ) Q1 2025 Earnings Call Transcript Jazz Pharmaceuticals succeeds in late-stage study of lung cancer treatment SA Asks: What are ...

    • June 10, 2025 08:36:39 am
    • |
    • SeekingAlpha
    • |
      • JAZZ Stock
      • JAZZ Quote
      • JAZZ Short
      • JAZZ News
      • JAZZ Articles
      • JAZZ Message Board
  • JAZZ - Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer

    Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer PR Newswire Target Action (PDUFA) Date set for October 7, 2025 Application ...

    • June 10, 2025 07:05:00 am
    • |
    • PR Newswire
    • |
      • JAZZ Stock
      • JAZZ Quote
      • JAZZ Short
      • JAZZ News
      • JAZZ Articles
      • JAZZ Message Board
  • JAZZ - Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Outcomes in Narcolepsy at SLEEP 2025

    Jazz Pharmaceuticals Presents Late-Breaking Phase 4 Data Showcasing Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Outcomes in Narcolepsy at SLEEP 2025 PR Newswire First presentation of the Phase 4 XYLO switch study reports blood press...

    • June 09, 2025 06:00:00 pm
    • |
    • PR Newswire
    • |
      • JAZZ Stock
      • JAZZ Quote
      • JAZZ Short
      • JAZZ News
      • JAZZ Articles
      • JAZZ Message Board
Next 10
Stock Information

Get JAZZ Alerts

News, Short Squeeze, Breakout and More Instantly...

Jazz Pharmaceuticals plc Company Name:

JAZZ Stock Symbol:

NASDAQ Market:

0.98% G/L:

$112.48 Last:

768,861 Volume:

$110.51 Open:

$112.48 Close:

Jazz Pharmaceuticals plc Website:

Jazz Pharmaceuticals plc Logo

Ad

Investor Relations
RECENT JAZZ NEWS
  • JAZZ - Jazz Pharmaceuticals Names Renee Gala as President and Chief Executive Officer

    Jazz Pharmaceuticals Names Renee Gala as President and Chief Executive Officer PR Newswire – Selection Follows Robust Succession Process Led by the Board – – Bruce Cozadd to Retire as CEO and Remain Chairperson of the Board of Directors ȁ...

  • JAZZ - Jazz Pharmaceuticals Receives European Commission Marketing Authorization for Ziihera® (zanidatamab) for the Treatment of Advanced HER2-Positive Biliary Tract Cancer

    Jazz Pharmaceuticals Receives European Commission Marketing Authorization for Ziihera® (zanidatamab) for the Treatment of Advanced HER2-Positive Biliary Tract Cancer PR Newswire – Conditional approval based on positive results from the HERIZON-BTC-01 Phase 2b t...

  • JAZZ - Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer

    Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer PR Newswire Target Action (PDUFA) Date set for October 7, 2025 Application ...

  • Research
  • Stock Search
  • News Releases
  • Articles
  • Topics
  • Message Boards
  • Trending Stocks
  • Trending Feed
  • Trending Alerts
  • Watchlist
  • Short Information
  • Stock Wall
  • Link Twitter
  • Sign Up
  • Login
  • Contact

Link your X Account

Link your X Account to Market Wire News

When you linking your X Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your X account.

Be alerted of any news about your stocks and see what other stocks are trending.



Connect with Us

Join our Telegram Alerts Channel

Telegram

Join our Discord

Discord

Get JAZZ Alerts

Get JAZZ Alerts

News, Short Squeeze, Breakout and More Instantly...

Sign up or login to continue

Sign up or login to continue.


Forgot password?




Mobile Number Subscribers

Market Wire News provides notifications to customers about updates, service, reminders, or products. Current and new customers of Market Wire News will enter their mobile numbers on a web opt-in form https://marketwirenews.com. Supported Carriers are as follows Alltel, AT&T, Cincinnati Bell, Dobson Cellular Systems, Inter Op, MetroPCS®, Nextel Communications, Sprint PCS, T-Mobile®, U.S. Cellular®, Verizon Wireless, and Virgin Mobile U.S. T-Mobile® is not liable for delayed or undelivered messages. There are no premium charges for joining Market Wire News service. Message and data rates may apply. Subscribers to Market Wire News service may receive up to 500 per month.

How to Opt Out

To opt-out of the Market Wire News program, send or text STOP, END, QUIT, CANCEL or UNSUBSCRIBE to (844) 931-3999. An unsubscribe message will be sent to your number confirming the cancellation, but no more messages will be sent after that one.

Mobile Support

For support or information about a Market Wire News, send or text HELP to (844) 931-3999. Optionally, you may email support@marketwirenews.com.


Disclaimer

This electronic content is for the purposes of solicitation subscriptions for Market Wire News. Market Wire News expects to generate new advertisement revenue resulting from the distribution of this electronic content. The amount of which is unknown at this time. Market Wire News is not a registered investment adviser or broker-dealer. This electronic content does not provide a professional analysis of a any stock financial position. any stock's financial position and all other information regarding the featured Company should be verified directly with any stock. This electronic content is provided as an information service only, and any statements and opinions in this electronic content should not be construed as an offer or solicitation to buy or sell any security. Market Wire News accepts no liability for any loss arising from an investor's reliance on or use of this electronic content. An investment in any company is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Market Wire News does not own, buy, sell or plans to own, buy, sell, and of any stock's shares. This electronic content contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Please read our full disclaimer for compensation and more detailed information.

Advertise

Brand your company, advertise your products or services with our ad programs.

Advertise

Research

Stock Search

News Releases

Articles

Message Boards

Trending Stocks

Short Information

Stock Wall

Members

Log In

Sign Up

Stay Connected

| X

| Facebook

| BlueSky

| LinkedIn

| Telegram

| Discord


Contact

Privacy

Terms of Service

Disclaimer

© 2025 Market Wire News 1